Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534419 | 1.00 | FUCA1 (0.47) | FUCA1SIGMAR1ACHECYP1A2CYP3A4 | |
| SCHEMBL20401188 | 0.94 | FUCA1 (0.45) | FUCA1SIGMAR1ACHECYP1A2CYP3A4 | |
| SCHEMBL20417935 | 0.80 | SIGMAR1 (0.37) | SIGMAR1ACHE | |
| SCHEMBL6973456 | 0.79 | SIGMAR1 (0.47) | SIGMAR1ACHEDRD4 | |
| SCHEMBL31346974 | 0.78 | SIGMAR1 (0.53) | FUCA1SIGMAR1ACHECYP1A2CYP3A4 | |
| SCHEMBL30655487 | 0.78 | FUCA1 (0.51) | FUCA1SIGMAR1ACHECYP1A2CYP3A4 | |
| SCHEMBL21220352 | 0.78 | CHRNB2 (0.51) | ALDH1A1 | |
| SCHEMBL24767528 | 0.75 | FUCA1 (0.53) | FUCA1SIGMAR1ACHEALDH1A1 | |
| SCHEMBL21737899 | 0.75 | FUCA1 (0.53) | FUCA1SIGMAR1ACHEALDH1A1 | |
| SCHEMBL12078355 | 0.75 | FUCA1 (0.49) | FUCA1SIGMAR1ACHECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | FUCA1 4786/4885SIGMAR1 2172/4885ACHE 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.